Liver Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1091-1095
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1091
Table 1 Patient characteristics, maximum toxicity, maximum response, adverse events, and arterial hypovascularisation under therapy.
Patient numberAge (yr)GenderMaximum number of gemcitabine cyclesMaximum number of chemo- occlusion cyclesMaximum responseNeutro- penia acc. To WHOThrombo- penia acc. To WHOAnemia acc. To WHOCholes- tasis acc. To WHONausea acc. To WHOFlush symptoms acc. To WHOTumor- related diseaseClinical therapy related benefitProgressive arterial hypovascu- larization
160M52SD222221yes--
271F41SD221221yes--
367F113PR111201--yes
447F73 (+11)PR101122yes-yes
563F92 (+11)PR001211yesyesyes
676F62 (+11)SD000011yesyesyes
753F92SD011222yesyes-
856M41SD002212yes--